A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Public ClinicalTrials.gov record NCT01447706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Study identification
- NCT ID
- NCT01447706
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Enrollment
- 223 participants
Conditions and interventions
Interventions
- MM-121 Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2011
- Primary completion
- Aug 31, 2013
- Completion
- May 31, 2015
- Last update posted
- May 11, 2016
2011 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Center for Cancer Care | Glendale | Arizona | 85306 | — |
| Pinnacle Oncology | Scottsdale | Arizona | 85258 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| Wilshire Oncology Medical Group | Corona | California | 92879 | — |
| North County Oncology | Oceanside | California | 92056 | — |
| Central Coast Medical Oncology | Santa Maria | California | 93454 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Carolinas Medical Center/Blumenthal Cancer Center | Charlotte | North Carolina | 28203 | — |
| ProMedica Health System, Inc. | Toledo | Ohio | 43606 | — |
| Chattanooga GYN Oncology | Chattanooga | Tennessee | 37403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01447706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2016 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01447706 live on ClinicalTrials.gov.